(NASDAQ:CDTX), SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness […]

(NasdaqGM:CRVS), SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company's Board of Directors. Mr. Moore brings a wealth of

(NASDAQ:ACHV), SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve's board of directors approved stock option grants

(TSX:CBNK), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF has declared a monthly cash distribution in the amount of $0.058333 per unit, payable on November 7, 2025 to unitholders of record on October 31, 2025. For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172,

(TSX:MPY), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — (TSX: MPY) Mulvihill Premium Yield Fund has declared a monthly cash distribution for its ETF Class in the amount of $0.06400 per unit, payable on November 7, 2025 to unitholders of record on October 31, 2025. For further information, please contact Investor Relations at 416.681.3966, toll free

(TSX:PIC-A),(TSX:PIC.PR.A),(TSX:PIC-PA.TO), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — (TSX: PIC.A; PIC.PR.A) Premium Income Corporation has declared monthly distributions payable on October 31, 2025, to shareholders of record on October 15, 2025, in the following amounts per share: Share Class Ticker Amount Per Share Class A Shares PIC.A $0.08000 Preferred Shares PIC.PR.A $0.10625 To the extent

(TSX: PGIC-PA),(TSX:PGIC-A),(TSX:PGIC), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — (TSX: PGIC; PGIC.PR.A) Premium Global Income Split Corp. has declared monthly distributions payable on October 31, 2025 to shareholders of record on October 15, 2025 in the following amounts per share: Share Class Ticker Amount Per Share Class A Shares PGIC $0.08000 Preferred Shares PGIC.PR.A $0.06250 To

(TSX:SPFD), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF has declared a monthly cash distribution in the amount of $0.08333 per unit, payable on November 7, 2025 to unitholders of record on October 31, 2025. For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172,

(NasdaqGM:FATE), SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2025 the Company granted to one newly-hired non-executive employee (i)

(NASDAQ:PRAX), BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on October 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock